Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 3.270
-0.020 (-0.61%)
At close: Feb 13, 2026
SHE:002589 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -0.09 | 20.62 | 20.32 | -1,831 | 131.18 | 261.3 |
Depreciation & Amortization | 164.77 | 164.77 | 219.68 | 283.88 | 319.22 | 291.41 |
Other Amortization | 51.28 | 51.28 | 25.75 | 32.88 | 44.42 | 46.39 |
Loss (Gain) From Sale of Assets | -18.94 | -18.94 | 7.92 | 1 | -3.06 | -3.78 |
Asset Writedown & Restructuring Costs | 0.61 | 0.61 | 4.91 | 47.83 | 39.9 | 25.43 |
Loss (Gain) From Sale of Investments | -114.4 | -114.4 | -424.59 | 656.44 | -103.46 | -226.57 |
Provision & Write-off of Bad Debts | 43.12 | 43.12 | 10.01 | 159.22 | 158.77 | 123.63 |
Other Operating Activities | 277.81 | 228.3 | 651.21 | 1,036 | 822.64 | 1,031 |
Change in Accounts Receivable | 61.01 | 61.01 | 1,122 | -6,340 | -197.21 | -198.13 |
Change in Inventory | 385.04 | 385.04 | -165.26 | 190.72 | 476.9 | 377.99 |
Change in Accounts Payable | -660.28 | -660.28 | -1,219 | 6,314 | -1,069 | -1,254 |
Operating Cash Flow | 189.25 | 160.44 | 82.47 | 523.07 | 442.95 | 414.96 |
Operating Cash Flow Growth | - | 94.56% | -84.23% | 18.09% | 6.75% | -80.19% |
Capital Expenditures | -161.64 | -111.53 | -298.38 | -170.96 | -461.09 | -640.15 |
Sale of Property, Plant & Equipment | -17.37 | 0.75 | 0.71 | 83.97 | 13.35 | 2.19 |
Cash Acquisitions | - | - | - | -70.37 | -173.27 | -358.5 |
Divestitures | 127.4 | 224.06 | 1,163 | 982.53 | 82.08 | 313.89 |
Investment in Securities | -29.93 | 90.5 | -285.98 | -297.63 | -80.58 | -491.53 |
Other Investing Activities | -107.92 | 0.2 | 0.3 | 32.77 | 20.44 | 26.81 |
Investing Cash Flow | -189.47 | 203.98 | 579.53 | 592.96 | -583.51 | -972.71 |
Short-Term Debt Issued | - | 18,568 | 20,785 | 6,271 | 8,480 | 8,531 |
Long-Term Debt Issued | - | 2,713 | 5,406 | 11,159 | 11,066 | 13,059 |
Total Debt Issued | 19,351 | 21,280 | 26,191 | 17,430 | 19,547 | 21,591 |
Short-Term Debt Repaid | - | -18,310 | -22,609 | -14,030 | -12,372 | -3,460 |
Long-Term Debt Repaid | - | -2,963 | -3,975 | -4,347 | -6,824 | -9,802 |
Total Debt Repaid | -20,080 | -21,273 | -26,584 | -18,377 | -19,196 | -13,261 |
Net Debt Issued (Repaid) | -729.32 | 6.96 | -393.11 | -947.42 | 350.84 | 8,330 |
Issuance of Common Stock | 78.61 | 78.61 | 26.3 | 68.7 | 4.24 | 8.56 |
Repurchase of Common Stock | -33.34 | -33.34 | -28.54 | -29.58 | -4.4 | -8.03 |
Common Dividends Paid | -191.53 | -198.71 | -201.69 | -154.31 | -316.31 | -346.56 |
Other Financing Activities | 752.63 | - | -80.15 | -402.52 | -84.78 | -9,065 |
Financing Cash Flow | -122.95 | -146.47 | -677.2 | -1,465 | -50.42 | -1,081 |
Foreign Exchange Rate Adjustments | - | - | -0 | 0 | -0 | 0 |
Net Cash Flow | -123.17 | 217.95 | -15.2 | -349.09 | -190.98 | -1,639 |
Free Cash Flow | 27.61 | 48.92 | -215.92 | 352.11 | -18.13 | -225.19 |
Free Cash Flow Margin | 0.38% | 0.61% | -2.69% | 2.86% | -0.09% | -0.83% |
Free Cash Flow Per Share | 0.02 | 0.03 | -0.14 | 0.24 | -0.01 | -0.15 |
Cash Interest Paid | 20.68 | 20.68 | 19.57 | 36.58 | 43.35 | 0.3 |
Cash Income Tax Paid | 146.11 | 165.85 | 135.3 | 398.68 | 928.46 | 1,055 |
Levered Free Cash Flow | 1,033 | -106.62 | -3,610 | 4,920 | 5,678 | -2,201 |
Unlevered Free Cash Flow | 1,148 | 14.55 | -3,421 | 5,175 | 6,024 | -1,817 |
Change in Working Capital | -214.92 | -214.92 | -432.75 | 136.28 | -966.67 | -1,134 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.